Cellontec, a subsidiary of SC Engineering, is entering the completion process of a new bio-collagen medical device factory to respond to the expanding demand in overseas markets such as China.
Cellontec announced on the 11th that it has signed a consulting contract with SPK, a GMP (Good Manufacturing Practice) consulting specialist, for concept design and validation (the process of verifying the final process integrity before commercial production of medical devices) of the new bio-collagen medical device factory located in Geumgok General Industrial Complex, Namyangju-si, Gyeonggi-do, accelerating efforts to increase productivity.
The new bio-collagen medical device factory of Cellontec will have a total floor area of 16,670㎡ (approximately 5,000 pyeong). After completing the building construction in the first half of last year, the goal is to complete the factory and start full-scale production by 2026.
Upon completion, Cellontec’s new bio-collagen medical device factory will secure a production base for bio-collagen raw materials and medical devices that meets US cGMP and European EU-GMP standards, with production capacity increased more than fivefold compared to the existing facility.
Cellontec is a regenerative treatment medical device specialist company based on proprietary bio-collagen raw materials registered in the US FDA Drug Master File (DMF). It supplies various products domestically and internationally, including intra-articular injection 'Katizol', cosmetic filler 'Therapil', and tendon/ligament reconstruction product 'Regenseal'.
Through joint marketing with LG Chem, Kolon Pharmaceutical, and Dongkook Pharmaceutical, Cellontec has established a stable foundation for expanding the domestic market. Additionally, based on cooperation with numerous partners such as Sahuan Pharmaceutical and Just Medical Device in China, it has secured a minimum order quantity (MOQ) worth approximately KRW 125 billion in overseas markets.
Since becoming a subsidiary of SC Engineering in 2021, Cellontec’s sales have more than doubled from KRW 7.2 billion to KRW 18.2 billion last year, achieving its highest-ever sales.
A Cellontec representative stated that by accelerating the completion of the new bio-collagen medical device factory, "We plan to proactively resolve the current saturation of production capacity caused by market demand exceeding supply." They added, "Furthermore, we will prepare for deliveries related to existing overseas supply contracts such as the launch of 'Therapil' and 'Katizol' in the Chinese market, and actively respond to various supply proposals in the global regenerative medicine and cosmetic surgery markets."
They continued, "With the operation of the new bio-collagen medical device factory as a turning point, Cellontec will establish a solid mid- to long-term growth foundation where overseas sales surpass domestic sales."
According to market research firms Cognitive Market Research and Coherent Market Insight, the global cosmetic filler market size is estimated to reach USD 13.5142 billion (approximately KRW 19.8 trillion) in 2024, and the global intra-articular injection market is expected to grow to USD 3.288 billion (approximately KRW 4.8 trillion) by 2027.
Meanwhile, in January, EV Advanced Materials became the effective largest shareholder of SC Engineering, the parent company of Cellontec, securing management rights over SC Engineering and Cellontec.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
